Can't find what you are looking for? Use our Antibody Concierge Service & we will help you locate your antibody!
Or feel free to contact us for alternative products.
Datasheet
Reviews & Publications
Protocols & FAQs
Support & Research
Human IL-33 ELISA Kit (Colorimetric) Summary
Specificity
Measures free IL-33 in the supernatant of activated cells.
Standard Curve Range
15-8000 pg/ml
Sensitivity
15 pg/ml
Assay Type
Sandwich ELISA
Sample Volume
0.1 ml
Kit Type
ELISA Kit (Colorimetric)
Gene
IL33
Applications/Dilutions
Dilutions
ELISA
Application Notes
For the Detection of Human IL-33 in the Supernatant. The human IL-33 ActivELISA(TM) Kit measures free IL-33 in the supernatant of activated cells. Standard protocols for detecting IL-33 activity include ELISA and Western Blot. The IL-33 ActivELISA(TM) can be completed in one day using a sandwich ELISA protocol. The anti-IL-33 antibody is coated on a plate which then captures free IL-33. The amount of bound IL-33 is detected by adding a second biotinylated anti-IL-33 antibody followed by HRP-conjugated streptavidin. ABTS substrate is then added and the concentration is determined by colorimetric detection in an ELISA plate reader.
Recombinant IL-33 Standard 1 vial lyophilized(0.1 ug)
Notes
Additional items required for the ELISA (not included in the IL-33 ActivELISA Module): 96-well ELISA plate reader
Alternate Names for Human IL-33 ELISA Kit (Colorimetric)
C9orf26
C9orf26chromosome 9 open reading frame 26 (NF-HEV)
DKFZp586H0523
DVS27
DVS27-related protein
IL1F11
IL-1F11
IL33
IL-33
interleukin 33
Interleukin-1 family member 11
interleukin-33
NFHEV
NF-HEV
NF-HEVNFEHEV
Nuclear factor from high endothelial venules
RP11-575C20.2
Background
IL-33 is a member of the Interleukin-1 family. It performs dual roles, both as a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties, as well. It is synthesized as a 30-kDa precursor, which is cleaved by Caspase 1 to generate an 18-kDa fragment, which is sufficient to activate signaling by the IL-33 receptor T1/ST2. IL-33 induces helper T cells, mast cells, eosinophils and basophils to produce type 2 cytokines. It directly stimulates eosinophil differentiation from CD117+ progenitors in an IL-5-dependent manner. IL-33/ST2 signaling pathway activates airway eosinophils that exacerbate airway inflammation in an autocrine and paracrine manner. IL-33 signaling through ST2 receptor involves the recruitment of the adaptor protein MyD88, IRAK1, IRAK4, and TRAF6, activating MAPKs and NF-kappaB, thereby regulating the transcription of cytokines typically associated with a Th2 response such as IL-4, IL-5, and IL-13 (Foo Y et al, 2011). The affinity of IL-33 for ST2L is enhanced in the presence of IL-1RAcP. IL-33 plays a significant role in the amplification of AAM polarization and chemokine production, which contribute to innate and Ag-induced airway inflammation. It strongly amplifies the expression of Arginase I and Ym1 as well as the production of CCL24 and CCL17, which may further recruit inflammatory cells. It also enhanced the eosinophil-mediated differentiation of airway macrophages toward the alternatively activated macrophage phenotype in an IL-13-dependent manner. IL-33 induces TLR4 expression on macrophages, rendering them more responsive to LPS stimulation. Unprocessed IL-33 accumulates in the nucleus, where it acts as a transcriptional repressor. IL-33 orchestrates its potential role as a mediator in the pathophysiology of many diseases such as cardiovascular disorder, asthma and rheumatoid arthritis (Bartosz Stolarski et al, 2011).
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. ELISA Kits are guaranteed for 6 months from date of receipt.
Interleukin 33 (IL-33) - A dual function cytokine IL-33 is a member of the interleukin family of cytokines that regulates a wide variety of cellular functions. Its receptor is ST2, an IL-1 receptor family member that also acts as a negative regulator of TLR-IL-1R signaling and the IL-1R accessory ... Read full blog post.